Company · CIK 0000879169 · SIC 8731 — Services-Commercial Physical & Biological Research · Nasdaq
INCYTE CORP · INCY
Insider activity reported against this company. All insider holders · Files at: AGEN, MRUS. On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 6, 2015 MForm 4 → | Apr 8, 4:17 pm EDT | Richard S LevyEVP, Chief Drug Dev Officer | 25,000 | $18.32 | $458,000 | 46,227 | — | plan? |
| Mar 30, 2015 SForm 4 → | Apr 1, 4:27 pm EDT | Laurent ChardonnetOther | 113,776 | $93.64 | $10,653,985 | 2,905 | −97.5% | plan? |
| Mar 30, 2015 MForm 4 → | Apr 1, 4:27 pm EDT | Laurent ChardonnetOther | 113,776 | $16.61 | $1,889,296 | 116,681 | — | plan? |
| Mar 30, 2015 SForm 4 → | Apr 1, 4:26 pm EDT | Reid M HuberEVP, Chief Scientific Officer | 34,263 | $93.66 | $3,209,206 | 44,408 | −43.6% | plan? |
| Mar 30, 2015 MForm 4 → | Apr 1, 4:26 pm EDT | Reid M HuberEVP, Chief Scientific Officer | 34,263 | $18.06 | $618,813 | 78,671 | — | plan? |
| Mar 16, 2015 SForm 4 → | Mar 18, 4:33 pm EDT | Paula J SwainEVP, Human Resources | 17,500 | $89.97 | $1,574,475 | 21,083 | −45.4% | plan? |
| Mar 16, 2015 MForm 4 → | Mar 18, 4:33 pm EDT | Paula J SwainEVP, Human Resources | 17,500 | $3.11 | $54,425 | 38,583 | — | plan? |
| Mar 12, 2015 SForm 4 → | Mar 13, 4:28 pm EDT | Barry A ArikoDirector | 80,000 | $89.27 | $7,141,600 | 45,834 | −63.6% | plan? |
| Mar 12, 2015 MForm 4 → | Mar 13, 4:28 pm EDT | Barry A ArikoDirector | 80,000 | $5.96 | $476,800 | 125,834 | — | plan? |
| Mar 12, 2015 SForm 4 → | Mar 13, 4:27 pm EDT | Eric H. SiegelEVP, General Counsel | 2,222 | $89.71 | $199,347 | 3,355 | −39.8% | plan? |
| Mar 12, 2015 MForm 4 → | Mar 13, 4:27 pm EDT | Eric H. SiegelEVP, General Counsel | 2,222 | $18.32 | $40,707 | 4,466 | — | plan? |
| Mar 10, 2015 MForm 4 → | Mar 10, 5:36 pm EDT | Yao WenqingEVP, Discovery Medicinal and P | 4,404 | $17.90 | $78,820 | 43,720 | — | plan? |
| Mar 6, 2015 SForm 4 → | Mar 10, 5:13 pm EDT | Richard S LevyEVP, Chief Drug Dev Officer | 25,000 | $89.91 | $2,247,750 | 21,227 | −54.1% | plan? |
| Mar 6, 2015 MForm 4 → | Mar 10, 5:13 pm EDT | Richard S LevyEVP, Chief Drug Dev Officer | 25,000 | $18.32 | $458,000 | 46,227 | — | plan? |
| Mar 5, 2015 SForm 4 → | Mar 9, 4:37 pm EDT | Eric H. SiegelEVP, General Counsel | 13,333 | $90.00 | $1,199,970 | 3,355 | −79.9% | plan? |
| Mar 5, 2015 MForm 4 → | Mar 9, 4:37 pm EDT | Eric H. SiegelEVP, General Counsel | 13,333 | $18.32 | $244,261 | 16,688 | — | plan? |
| Mar 5, 2015 SForm 4 → | Mar 9, 4:35 pm EDT | Richard U De SchutterDirector | 40,000 | $92.09 | $3,683,759 | 92,290 | −30.2% | plan? |
| Mar 5, 2015 MForm 4 → | Mar 9, 4:35 pm EDT | Richard U De SchutterDirector | 40,000 | $16.16 | $646,200 | 99,821 | — | plan? |
| Feb 25, 2015 SForm 4 → | Feb 25, 5:29 pm EST | Eric H. SiegelEVP, General Counsel | 13,333 | $85.00 | $1,133,305 | 3,355 | −79.9% | plan? |
| Feb 25, 2015 MForm 4 → | Feb 25, 5:29 pm EST | Eric H. SiegelEVP, General Counsel | 13,333 | $18.32 | $244,261 | 16,688 | — | plan? |
| Feb 23, 2015 SForm 4 → | Feb 25, 5:29 pm EST | James M DalyEVP, Chief Commercial Officer | 11,112 | $82.19 | $913,268 | 3,521 | −75.9% | plan? |
| Feb 23, 2015 MForm 4 → | Feb 25, 5:29 pm EST | James M DalyEVP, Chief Commercial Officer | 11,112 | $17.05 | $189,404 | 11,855 | — | plan? |
| Feb 18, 2015 SForm 4 → | Feb 20, 4:43 pm EST | Barry A ArikoDirector | 20,000 | $78.43 | $1,568,600 | 45,834 | −30.4% | plan? |
| Feb 18, 2015 MForm 4 → | Feb 20, 4:43 pm EST | Barry A ArikoDirector | 20,000 | $7.68 | $153,600 | 65,834 | — | plan? |
| Feb 17, 2015 SForm 4 → | Feb 18, 5:49 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 12,000 | $76.90 | $922,800 | 18,205 | −39.7% | plan? |
| Feb 17, 2015 MForm 4 → | Feb 18, 5:49 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 12,000 | $15.66 | $187,947 | 30,205 | — | plan? |
| Feb 17, 2015 SForm 4 → | Feb 18, 5:47 pm EST | Paula J SwainEVP, Human Resources | 17,500 | $76.90 | $1,345,750 | 21,083 | −45.4% | plan? |
| Feb 17, 2015 MForm 4 → | Feb 18, 5:47 pm EST | Paula J SwainEVP, Human Resources | 17,500 | $3.11 | $54,425 | 38,583 | — | plan? |
| Feb 13, 2015 FForm 4 → | Feb 18, 5:50 pm EST | Herve HoppenotChief Executive Officer, Director | 30,534 | $75.94 | $2,318,752 | 382,058 | — | plan? |
| Feb 13, 2015 SForm 4 → | Feb 18, 5:49 pm EST | Paul A FriedmanDirector | 120,000 | $74.32 | $8,918,400 | 297,518 | −28.7% | plan? |
| Feb 6, 2015 SForm 4 → | Feb 10, 4:33 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 25,000 | $75.11 | $1,877,750 | 18,205 | −57.9% | plan? |
| Feb 6, 2015 MForm 4 → | Feb 10, 4:33 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 25,000 | $18.32 | $458,000 | 43,205 | — | plan? |
| Jan 23, 2015 SForm 4 → | Jan 26, 4:57 pm EST | James M DalyEVP, Chief Commercial Officer | 11,109 | $77.68 | $862,947 | 3,521 | −75.9% | plan? |
| Jan 23, 2015 MForm 4 → | Jan 26, 4:57 pm EST | James M DalyEVP, Chief Commercial Officer | 11,109 | $17.04 | $189,352 | 14,630 | — | plan? |
| Jan 22, 2015 SForm 4 → | Jan 26, 4:57 pm EST | Eric H. SiegelEVP, General Counsel | 13,542 | $79.85 | $1,081,266 | 3,355 | −80.1% | plan? |
| Jan 22, 2015 MForm 4 → | Jan 26, 4:57 pm EST | Eric H. SiegelEVP, General Counsel | 13,542 | $17.79 | $240,912 | 4,397 | — | plan? |
| Jan 20, 2015 SForm 4 → | Jan 20, 5:28 pm EST | Paula J SwainEVP, Human Resources | 17,500 | $74.17 | $1,297,975 | 21,083 | −45.4% | plan? |
| Jan 20, 2015 MForm 4 → | Jan 20, 5:28 pm EST | Paula J SwainEVP, Human Resources | 17,500 | $3.11 | $54,425 | 38,583 | — | plan? |
| Jan 16, 2015 SForm 4 → | Jan 20, 5:27 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 12,000 | $73.07 | $876,840 | 18,205 | −39.7% | plan? |
| Jan 16, 2015 MForm 4 → | Jan 20, 5:27 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 12,000 | $14.72 | $176,640 | 30,205 | — | plan? |
| Jan 8, 2015 SForm 4 → | Jan 12, 5:06 pm EST | Eric H. SiegelEVP, General Counsel | 15,626 | $75.00 | $1,171,950 | 3,355 | −82.3% | plan? |
| Jan 8, 2015 MForm 4 → | Jan 12, 5:06 pm EST | Eric H. SiegelEVP, General Counsel | 15,626 | $16.78 | $262,194 | 18,981 | — | plan? |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:03 pm EST | Yao WenqingEVP, Discovery Medicinal and P | 3,022 | — | — | 39,316 | — | plan? |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:02 pm EST | Paula J SwainEVP, Human Resources | 3,022 | — | — | 21,083 | — | plan? |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:02 pm EST | Eric H. SiegelEVP, General Counsel | 3,022 | — | — | 3,355 | — | plan? |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:01 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 3,022 | — | — | 21,227 | — | plan? |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:01 pm EST | Reid M HuberEVP, Chief Scientific Officer | 3,022 | — | — | 44,562 | — | plan? |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:01 pm EST | Herve HoppenotChief Executive Officer, Director | 12,592 | — | — | 412,592 | — | plan? |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:00 pm EST | David W GryskaExecutive Vice President, CFO | 3,022 | — | — | 10,850 | — | plan? |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:00 pm EST | Barry P FlannellyEVP, Business Development | 3,022 | — | — | 3,022 | — | plan? |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:00 pm EST | James M DalyEVP, Chief Commercial Officer | 3,022 | — | — | 3,521 | — | plan? |
| Jan 8, 2015 AForm 4 → | Jan 9, 6:59 pm EST | Laurent ChardonnetOther | 1,152 | — | — | 2,905 | — | plan? |
| Jan 6, 2015 SForm 4 → | Jan 8, 5:34 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 25,000 | $71.84 | $1,796,000 | 18,205 | −57.9% | plan? |
| Jan 6, 2015 MForm 4 → | Jan 8, 5:34 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 25,000 | $18.32 | $458,000 | 43,205 | — | plan? |
| Jan 5, 2015 SForm 4 → | Jan 7, 4:29 pm EST | Paula J SwainEVP, Human Resources | 17,500 | $73.90 | $1,293,250 | 18,061 | −49.2% | plan? |
| Jan 5, 2015 MForm 4 → | Jan 7, 4:29 pm EST | Paula J SwainEVP, Human Resources | 17,500 | $3.11 | $54,425 | 35,561 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 23, 2015 MForm 4 → | Apr 24, 4:20 pm EDT | James M DalyEVP, Chief Commercial Officer | 36,941 | — | — | 19,624 | — | |
| Apr 16, 2015 MForm 4 → | Apr 17, 5:10 pm EDT | Reid M HuberEVP, Chief Scientific Officer | 10,060 | — | — | 0 | — | |
| Apr 14, 2015 MForm 4 → | Apr 16, 4:29 pm EDT | Eric H. SiegelEVP, General Counsel | 2,222 | — | — | 6,735 | — | |
| Apr 13, 2015 MForm 4 → | Apr 14, 4:15 pm EDT | Paula J SwainEVP, Human Resources | 16,469 | — | — | 0 | — | |
| Apr 10, 2015 MForm 4 → | Apr 14, 4:14 pm EDT | Yao WenqingEVP, Discovery Medicinal and P | 23,000 | — | — | 35,354 | — | |
| Apr 7, 2015 MForm 4 → | Apr 8, 4:18 pm EDT | Yao WenqingEVP, Discovery Medicinal and P | 5,000 | — | — | 58,354 | — | |
| Apr 6, 2015 MForm 4 → | Apr 8, 4:17 pm EDT | Richard S LevyEVP, Chief Drug Dev Officer | 25,000 | — | — | 41,782 | — | |
| Mar 30, 2015 MForm 4 → | Apr 1, 4:27 pm EDT | Laurent ChardonnetOther | 113,776 | — | — | 0 | — | |
| Mar 30, 2015 MForm 4 → | Apr 1, 4:26 pm EDT | Reid M HuberEVP, Chief Scientific Officer | 34,263 | — | — | 0 | — | |
| Mar 16, 2015 MForm 4 → | Mar 18, 4:33 pm EDT | Paula J SwainEVP, Human Resources | 17,500 | — | — | 16,469 | — | |
| Mar 12, 2015 MForm 4 → | Mar 13, 4:28 pm EDT | Barry A ArikoDirector | 80,000 | — | — | 0 | — | |
| Mar 12, 2015 MForm 4 → | Mar 13, 4:27 pm EDT | Eric H. SiegelEVP, General Counsel | 2,222 | — | — | 7,021 | — | |
| Mar 10, 2015 MForm 4 → | Mar 10, 5:36 pm EDT | Yao WenqingEVP, Discovery Medicinal and P | 4,404 | — | — | 0 | — | |
| Mar 6, 2015 MForm 4 → | Mar 10, 5:13 pm EDT | Richard S LevyEVP, Chief Drug Dev Officer | 25,000 | — | — | 66,782 | — | |
| Mar 5, 2015 MForm 4 → | Mar 9, 4:37 pm EDT | Eric H. SiegelEVP, General Counsel | 13,333 | — | — | 7,307 | — | |
| Mar 5, 2015 MForm 4 → | Mar 9, 4:35 pm EDT | Richard U De SchutterDirector | 40,000 | — | — | 0 | — | |
| Feb 25, 2015 MForm 4 → | Feb 25, 5:29 pm EST | Eric H. SiegelEVP, General Counsel | 13,333 | — | — | 7,593 | — | |
| Feb 23, 2015 MForm 4 → | Feb 25, 5:29 pm EST | James M DalyEVP, Chief Commercial Officer | 11,112 | — | — | 4,813 | — | |
| Feb 18, 2015 MForm 4 → | Feb 20, 4:43 pm EST | Barry A ArikoDirector | 20,000 | — | — | 0 | — | |
| Feb 17, 2015 MForm 4 → | Feb 18, 5:49 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 12,000 | — | — | 0 | — | |
| Feb 17, 2015 MForm 4 → | Feb 18, 5:47 pm EST | Paula J SwainEVP, Human Resources | 17,500 | — | — | 33,969 | — | |
| Feb 6, 2015 MForm 4 → | Feb 10, 4:33 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 25,000 | — | — | 91,782 | — | |
| Jan 23, 2015 MForm 4 → | Jan 26, 4:57 pm EST | James M DalyEVP, Chief Commercial Officer | 11,109 | — | — | 30,655 | — | |
| Jan 22, 2015 MForm 4 → | Jan 26, 4:57 pm EST | Eric H. SiegelEVP, General Counsel | 13,542 | — | — | 0 | — | |
| Jan 20, 2015 AForm 4 → | Jan 22, 4:04 pm EST | Paul J ClancyDirector | 30,000 | — | — | 5,000 | — | |
| Jan 20, 2015 AForm 4 → | Jan 22, 4:04 pm EST | Jean Jacques BienaimeDirector | 30,000 | — | — | 5,000 | — | |
| Jan 20, 2015 MForm 4 → | Jan 20, 5:28 pm EST | Paula J SwainEVP, Human Resources | 17,500 | — | — | 51,469 | — | |
| Jan 16, 2015 MForm 4 → | Jan 20, 5:27 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 12,000 | — | — | 8,317 | — | |
| Jan 8, 2015 MForm 4 → | Jan 12, 5:06 pm EST | Eric H. SiegelEVP, General Counsel | 15,626 | — | — | 0 | — | |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:03 pm EST | Yao WenqingEVP, Discovery Medicinal and P | 41,545 | — | — | 1,365 | — | |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:02 pm EST | Paula J SwainEVP, Human Resources | 21,545 | — | — | 1,356 | — | |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:02 pm EST | Eric H. SiegelEVP, General Counsel | 21,545 | — | — | 1,356 | — | |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:01 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 21,545 | — | — | 1,085 | — | |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:01 pm EST | Reid M HuberEVP, Chief Scientific Officer | 51,545 | — | — | 1,365 | — | |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:01 pm EST | Herve HoppenotChief Executive Officer, Director | 89,771 | — | — | 1,365 | — | |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:00 pm EST | David W GryskaExecutive Vice President, CFO | 21,545 | — | — | 599 | — | |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:00 pm EST | Barry P FlannellyEVP, Business Development | 21,545 | — | — | 599 | — | |
| Jan 8, 2015 AForm 4 → | Jan 9, 7:00 pm EST | James M DalyEVP, Chief Commercial Officer | 21,545 | — | — | 1,099 | — | |
| Jan 8, 2015 AForm 4 → | Jan 9, 6:59 pm EST | Laurent ChardonnetOther | 13,984 | — | — | 1,365 | — | |
| Jan 6, 2015 MForm 4 → | Jan 8, 5:34 pm EST | Richard S LevyEVP, Chief Drug Dev&Medical Of | 25,000 | — | — | 116,782 | — | |
| Jan 5, 2015 MForm 4 → | Jan 7, 4:29 pm EST | Paula J SwainEVP, Human Resources | 17,500 | — | — | 68,969 | — |
Filed by this entity as an insider elsewhere — common stock
| Trade | Reported (ET) | Company | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2017 PForm 4 → | Feb 14, 5:26 pm EST | AGENUS INCAGEN | 10,000,000 | $6.00 | $60,000,000 | 17,763,968 | +129% | plan? |
Filed by this entity as an insider elsewhere — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.